Clinical Trials
4 trialsNCT07472153 2026-05-28
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
N.N. Alexandrov National Cancer Centre
Phase 2/3 Recruiting
NCT06280495 2026-04-20
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
Phase 2/3 Recruiting
NCT07319429 2026-03-13
FEMUS
Fudan University
Phase 2/3 Recruiting
NCT04973306 2022-06-30
iCROSS
Shanghai Zhongshan Hospital
Phase 2/3 Recruiting